Sagimet Biosciences Inc. Series A Common Stock

Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

Sagimet Biosciences Provides Strategic and Corporate Updates

Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates